在开始基于聚乙二醇干扰素-α治疗的合并感染HIV的患者中，与丙型肝炎病毒清除相关的细胞因子反应
Cytokine Response Associated with Hepatitis C Virus Clearance in HIV Coinfected Patients Initiating Peg Interferon-α Based Therapy.
作者信息
Nguyen Truong Tam, Niloofar Reihani, Rubbo Pierre-Alain, Nils Kuster, Bollore Karine, Ducos Jacques, Pageaux Georges-Philippe, Reynes Jacques, Van de Perre Philippe, Tuaillon Edouard
机构信息
Université Montpellier 1, INSERM U 1058, 34394 Montpellier, France.; Pham Ngoc Thach University of Medicine, Thanh Thai, Ho Chi Minh City, Vietnam.
Université Montpellier 1, INSERM U 1058, 34394 Montpellier, France.
出版信息
Mediterr J Hematol Infect Dis. 2016 Jan 1;8(1):e2016003. doi: 10.4084/MJHID.2016.003. eCollection 2016.
BACKGROUND
Treatment of hepatitis C virus (HCV) infection based on peginterferon-α (pegIFNα) and ribavirin induces important changes in cytokine release and T cell activation.
OBJECTIVE
Immune response to pegIFNα-ribavirin therapy was explored in patients coinfected by HCV and HIV.
METHODS
Concentrations of 25 cytokines and CD8(+) T cell activation were monitored in HCV/HIV coinfected patients classified as sustained virological responders (SVR, n=19) and non-responders (NR, n=11).
RESULTS
High pretreatment concentrations of IP-10 (CXCL-10) and MCP-1 (CCL-2) were associated with a poor anti-HCV response. PegIFNα-ribavirin therapy increased CD8(+) T cell activation and induced significant changes in levels of eleven cytokines related to both Th1 and Th2 responses in SVR (IL-1β, IL-1RA, IL-4, IL-5, IL-6, IL-7, IL-12p40/70, IL-13, IP-10, eotaxin, MCP-1) but of only six cytokines in NR (IL-1β, IL-2, IL-5, IL-12p40/70, IL-13, eotaxin). The highest rise in MIP-1β and MCP-1 levels was observed four weeks after anti-HCV treatment initiation in SVR compared to NR (p=0.002 and p=0.03, respectively), whereas a decrease in IL-8 concentration was associated with treatment failure (p= 0.052).
CONCLUSIONS
Higher and broader cytokine responses to pegIFNα-ribavirin therapy were observed in SVR patients compared to NR. Changes in IL-8, MIP-1β, and MCP-1 serum concentrations may be associated with efficacy of pegIFNα- and ribavirin-based therapies in patients coinfected by HCV and HIV.
背景
基于聚乙二醇干扰素-α（pegIFNα）和利巴韦林的丙型肝炎病毒（HCV）感染治疗可引起细胞因子释放和T细胞活化的重要变化。
目的
探讨HCV和HIV合并感染患者对pegIFNα-利巴韦林治疗的免疫反应。
方法
在分类为持续病毒学应答者（SVR，n = 19）和无应答者（NR，n = 11）的HCV/HIV合并感染患者中监测25种细胞因子的浓度和CD8(+) T细胞活化情况。
结果
IP-10（CXCL-10）和MCP-1（CCL-2）的高治疗前浓度与抗HCV反应不佳相关。PegIFNα-利巴韦林治疗增加了CD8(+) T细胞活化，并在SVR患者中诱导了与Th1和Th2反应相关的11种细胞因子水平的显著变化（IL-1β、IL-1RA、IL-4、IL-5、IL-6、IL-7、IL-12p40/70、IL-13、IP-10、嗜酸性粒细胞趋化因子、MCP-1），但在NR患者中仅诱导了6种细胞因子的变化（IL-1β、IL-2、IL-5、IL-12p40/70、IL-13、嗜酸性粒细胞趋化因子）。与NR相比，SVR患者在抗HCV治疗开始后四周观察到MIP-1β和MCP-1水平的最高升高（分别为p = 0.002和p = 0.03），而IL-8浓度降低与治疗失败相关（p = 0.052）。
结论
与NR患者相比，SVR患者对pegIFNα-利巴韦林治疗观察到更高和更广泛的细胞因子反应。IL-8、MIP-1β和MCP-1血清浓度的变化可能与基于pegIFNα和利巴韦林的疗法对HCV和HIV合并感染患者的疗效相关。
Zotero 插件